The promise of immunotherapy is particularly evident in the recent success of antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD1)/PD-L1 immune checkpoints in promoting anti-tumor immune responses and extending survival in a number of cancer types (4). Here, CD274 is linked to neoplasm.